The FDA on 26 October 2012 granted accelerated approval for Synribo (omacetaxine mepesuccinate)from Cephalon/Teva to treat adults with Chronic Myelogenous...
The FDA has approved Synribo (omacetaxine mepesuccinate), from Teva, for injection, for subcutaneous use, to include home administration, and also...
Chronic myelogenous leukaemia: a remarkable success story Chronic myelogenous leukaemia (CML), or chronic granulocytic leukaemia, is a disease in which...